OSR (NASDAQ:OSRH) versus Inhibrx Biosciences (NASDAQ:INBX) Head to Head Analysis

Inhibrx Biosciences (NASDAQ:INBX) and OSR (NASDAQ:OSRH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Volatility and Risk

Inhibrx Biosciences has a beta of 3.81, meaning that its stock price is 281% more volatile than the S&P 500. Comparatively, OSR has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500.

Profitability

This table compares Inhibrx Biosciences and OSR’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-83.48%
OSR	-593.15%	-8.36%	-6.24%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Inhibrx Biosciences and OSR, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1	2	2	1	2.50
OSR	1	0	0	0	1.00

Inhibrx Biosciences presently has a consensus price target of $197.50, suggesting a potential upside of 110.84%. Given Inhibrx Biosciences’ stronger consensus rating and higher possible upside, research analysts plainly believe Inhibrx Biosciences is more favorable than OSR.

Institutional and Insider Ownership

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by insiders. Comparatively, 36.9% of OSR shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Inhibrx Biosciences and OSR”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30 million	1,060.69	-$140.05 million	($8.88)	-10.55
OSR	$1.81 million	4.17	-$27.06 million	($0.37)	-0.58

OSR has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks.

Summary

Inhibrx Biosciences beats OSR on 8 of the 15 factors compared between the two stocks.

About Inhibrx Biosciences

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.